In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings,...
Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression...
Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active...
Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables monitoring of adverse effects associated with Alzheimer's disease treatmentsHighlighted...
A roundup of the most newsworthy healthcare press releases from PR Newswire, including new company mergers, Alzheimer's fundraising and advances...
BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- A recent setback due to unexpected safety concern from a phase 2 study...
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)...
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire...
Interim data show substantial improvements in “Good On” time compared to other oral CD/LD therapiesCREXONT delivered substantial “Off” time reductions,...
Major Regulatory Milestone: The first Canadian-developed AI for ICH triage receives FDA clearance to enter the U.S. market.Operational Value: Automates...
LOUISVILLE, Ky., Dec. 4, 2025 /PRNewswire/ -- Sir Simon Baron-Cohen has received the 2026 Grawemeyer Award in Psychology, a distinction...
Preliminary results indicate HHT patients are significantly impacted by bleeding events, with consistency in severity reporting at months one and...
First video-documented ALS reversal marks a new era for brain health achieved through noninvasive computerized brain-temperature modulation, confirmed by electrophysiological,...
Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTH of...
Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of...
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCID: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical")...
MIDDLETON, Wis., Dec. 3, 2025 /PRNewswire/ -- Natus Medical Incorporated announced the electrographic status epilepticus diagnosis capability of its BrainWatch point-of-care...
New policy recognizes the Nerivio REN wearable as medically necessary for both acute and preventive treatment of migraine in patients...
Study in Lancet Digital Health represents the largest real-world evaluation of stroke AI imaging, encompassing data from more than 450,000...
FORT MYERS, Fla., Dec. 2, 2025 /PRNewswire/ -- Bridge To A Cure Foundation announces the appointment of Winston Ely to its...